



ISSN: 2520-5234

Available online at <http://www.sjomr.org>

SCIENTIFIC JOURNAL
OF MEDICAL RESEARCH

Vol. 4, Issue 15, pp 102 - 110, Summer 2020



REVIEW ARTICLE

SARS-COV2: Genome, Animal Reservoir, Laboratory Diagnosis and Treatment

Ayser Ashour Khalaf¹, Alaa Shahid Jassim AL-Bdery² and Zahraa J. Jameel³

¹ Department of Biology, Collage of Education for Pure Science, University of Kerbala, Kerbala, Iraq

² Department of Biology, Faculty of Education for Girls, University of Kufa, Al-Najaf, Iraq

³ Department of Biology, College of Science, University of Diyala, Diyala, Iraq

ARTICLE INFORMATION

Article History:

Submitted: 21 June 2020

Revised version received:

10 July 2020

Accepted: 14 July 2020

Published online: 1 September 2020

Key words:

"SARS-COV"2

Genom

Diagnosis

Reservoir

Treatment

Corresponding author:

Ayser Ashour Khalaf

Email: ayserashour78@gmail.com

Department of Biology

Collage of Education for Pure Science

University of Kerbala

Kerbala

Iraq

ABSTRACT

Background: The new virus genome sequencing that causes Covid 19 in China has been diagnosed in the Hubei province of China (accession number MG772933.1).

Objectives: The present study highlighted on the genetic diversity of covid-19 and showed the ways for diagnosis, the transmission and the variety of treatment that are used for covid -19.

Methods: including Specimens collection nasopharyngeal swab (NP), Oropharyngeal swab (OP), Molecular methods RT- PCR Diagnostic, Serological Methods ELISA technique and rapid antigen tests, Chest X-ray examination.

Results: As an outcomes demonstrated that the 5'-end of the genome comprise of orf1ab and orf1a qualities while proteins (S, E, M, and N) are situated in The 3'-end of the genome expansion to eight frill proteins (3a, 3b, p6, 7a, 7b, 8b, 9b, and orf14).

Conclusion: It shows that the inherited recombination event at S protein in the RBD territory of "SARS-CoV"-2 may have overhauled its transmission likewise the molecular analysis is the most exactness than different ways and There is no uncommon treatment for covid-19.

Copyright©2020, Ayser Ashour Khalaf, Alaa Shahid Jassim AL-Bdery and Zahraa J. Jameel. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution and reproduction in any medium, provided the original work is properly cited.

Citation: Khalaf A.A., AL-Bdery A.S.J. and Jameel Z.J. "SARS-COV2: Genome, Animal Reservoir, Laboratory Diagnosis and Treatment". Sci. J. Med. Res. 2020; 4 (15): 102- 110.

INTRODUCTION

The WHO has classified coronary disease 19 (COVID-19) as a pandemic ¹. In December of 2019 "severe acute respiratory syndrome coronavirus"-2. ("SARS-CoV" -2.) were recognized in "Wuhan", Hubei Province, China ². The ability to spread is one of the most important characteristics of this virus and causes severe diseases for patients and the elderly ^{3,4}. In Coronaviridae, coronavirus (CoV) belongs to the genus Coronavirus All RNA CoVs

are polymorphic and have a crown-shaped polymers because of the presence of spike glycoproteins on the envelope. By a size of 80-160 nm and positive schism 27-32 kb. It should be noted that these viruses are caused by mutation and reassembly ⁵. Because of the continuous expansion of copy mistakes and RNA Polymerase (RdRP) hops, very high recombination rates for CoVs. With high mutation rate, Coronaviruses are animal infectious agents

found in different humans and animals^{6,7}. For the first time, the "SARS-CoV"-2 gene sequence change has been reported. Where researchers believe that genetic variations may enhance the virulence of the virus over there 2 common strains, the fatal "L" strain and the less severe "S" strain⁸. According to open science, "SARS-CoV"-2 research is the fastest moving material in human history. Within months, thousands of data and reports were published regarding the origin, genomics, genome evolution, vaccine or treatments, and molecular diagnosis of COVID-19 have been published⁹⁻¹². "SARS-CoV"-2 is obtaining novel alterations in its genome, Even though several alterations offer advantages to the virus versus human body's defenses, a numeral of them might product in their decreased virulence and pathogenicity. Even though the source of the virus remains to be a unknown, has because the higher divergence in genomic sequence of virus caused COVID-19 to its potential origins Pangolin-CoV-2019 or Bat-CoV-RaTG13¹³ than antecedently anticipated¹⁴. The ordination of COVID-19 is suffering incessant development. Merely months after the virus was first reported^{15,16} there are over a hundred substitution sites known in COVID-19's macromolecule secret writing area. Greatest of those modifications area unit placed within the secret writing region of polyprotein 1ab (pp1ab, ORF1)¹⁷ and structural proteins¹⁸. The source mentioned that a previous study highlighted the evolution of the virus into double sub types (S and L) classified through 2 complete coupled one ester polymorphisms (SNPs) at ordination sites 28144 and 8792¹⁴. SNP 29144 results in associate degree aminoalkanoic acid modification from (L) L E U to (S) S E R in ORF 8, assuming it is meant to stay associated with infective agent replication¹⁹.¹⁴ Found that S is quite expected that a quantity is less antagonistic but more adaptable than L and in the coming it will increase with frequency⁵. Recent studies have indicated that one of the important mechanisms for the evolution of the virus in nature is the deletion and / or replacement of nucleotides and amino acids (AA) in the whole genome of "SARS-CoV"-2^{20,21}. Furthermore, high genomic diversity and rapid development of RNA viruses, receptor binding mutations (RBD), and new strains may help eliminate neutralization by antibodies targeting RBD²². Therefore, non-RBD functional areas of diabetes S can be efficiently chosen to develop effective preventive and curative interventions against "SARS-CoV"-2²³.

Genome

Several studies broke down qualities for entire or practically entire genomes of "SARS-CoV"-2 and found different erasures and transformations in cryptographic and non-coding locales. These studies offer help of the hereditary assortment and quick advancement of this new coronavirus²⁴. Chan *et al.* have affirmed that the genome of the "SARS-CoV"-2, separated from a cluster- patient with unordinary pneumonia after remain in "Wuhan", and had 82% nucleotide comparable with that of human "SARS-CoV" and 89% nucleotide comparative with bat SARS-like-CoVZXC21²⁵.

The total of open reading frames (ORFs) in the Coronavirus genome ranges from 6-14, which they

encoded 27 non basic proteins nsp²⁶. CoV hereditary material is defenseless for visit recombination process, which can offer ascent to new strains with modification in virulence²⁷. The RNA genome of Coronavirus has seven qualities that are put away in the plan: ORF1a, ORF1b, S, OEF3, E, M, N in 5' to 3' course. The two-third piece of the RNA genome is secured by the ORF1a/b, which yields the viral replicase, proteins polyproteins (PP1a and PP1ab) which they encoded chymotrypsin-like protease 3CLPro, Main protease Mpro and 1-2 papain – like protease to deliver 16 nonstructural proteins²⁸. Because of the lack of polymerase syntax checking activity, therefore, RNA viruses has a high mutation rate. This results in RNA viruses vulnerable to developing drug resistance and escape from immune surveillance. "SARS-CoV"-2 has yet to have a clear mutation rate. Nevertheless, bearing in mind that the average number of differences in the even-numbered sequence was 4 (the spring range, 3--6) of the 110 sequences obtained from December 24, 2019 to February 9, 2020, with a mutation rate of the same order in "SARS-CoV" (0.80-2.38 x 10⁻³ substitution of nucleotides for each site per year)²⁹. The great rate of mutation results in a great level of variables within the body in RNA viruses³⁰. The average total of intrahost variation in patients with COVID-19 was 4 for variations with frequency ≥ 5%, and this limit did not be different knowingly from that described in a studies on Ebola (655 variants by means of frequency ≥ 5% in 134 samples; P > .05)³¹.

In several "SARS-CoV"-2 isolates, mutations occur mostly in the following genes, S, N, ORF8, ORF3a, and ORF1ab, and there are approximately 42% of the differences representing non-synonymous mutation³². Studies have revealed an augmented level of viral variety in a number of patients with "SARS-CoV"-2, indicating the adapted to the human population, So genomes have originated to develop in the human population³³.

Considering the close evolutionary relationships, the genome building of CoV-2 SARS is not surprising like to that found in other betacoronaviruses viruses, with the order of the 5 - replicase genes ORF1ab -S- envelope (E) - membrane (M) -N - 3'. It exceeds 21 KB the length of the ORF1ab gene for "SARS-CoV"-2 and comprises 16 predictable non - structural proteins and the number of downstream open reading frames (ORFs), which may have a function similar to "SARS-CoV". An analysis assisted in a virus-related abundance of Renolophos Avene (i.e. horseshoe) when sampled in in Yunnan Province, China, in 2013 is comparative genomic analysis³⁴. This virus named RaTG13 is like ~96% for SARS - CoV - 2 at the nucleotide structure level³⁵. These are spike proteins consist of 2 subunit S 1 and S 2 that had 40% amino acids similar to other "SARS-COV". MERS-CoV and "SARS-CoV" spike proteins bind to diverse host receptors through diverse Receptor -Binding Domains (RBDs). The Angiotensin - Converting Enzyme 2 (ACE2) is used by "SARS-CoV" as one of the primary receptors³⁶, with CD209 L acting by means of an alternate receptor³⁷, while MERS-CoV uses dipeptidyl peptidase 4 (DPP4, as well known as CD26) as the main receptor. 2019-nCoV

has nearby evolutionary association by SARS-like coronavirus, as suggested by the Initial analysis³⁸. Significantly, orf3b encodes an entirely new short protein. Moreover, the novel orf8 is likely to encode a protein secreted by alpha helix, followed by a beta sheet (s) having six strands³⁹. Another noticeable thing about COVID-19 is the ORF10 that does not contain any similar proteins in a massive NCBI depot. ORF10 is a small protein or peptide with a length of 38 residues. This exclusive protein can be used to detect the virus faster than PCR-based methods⁴⁰. In the other hand the study of⁴¹ indicate of that when more than 3,000 high-coverage and full sequences of the genome deposited in the GISAID database were analyzed, unique: 28881 – 28883 : GGG> AAC three-nucleotide mass mutation in the "SARS-CoV"-2 genome that produces two sub-strains, designated here as "SARS-CoV"-2g (28881-28883: the GGG genotype) and "SARS-CoV"-2a (28881-28883: the AAC genotype). For nations with no elaborate facilities for whole-genome sequencing, RT-PCR based testing should be recommended by targeting 28881-28883 region. This will give diagnostic information on COVID-19 together with the information on the two sub-strains: "SARS-CoV"-2a and "SARS-CoV"-2g in an infected person. This will allow gathering valuable information about the prevalence of these two strains are prevalent in those countries. Potential medications can be designed to target the 28881-28883 N protein region for modifying virus pathogenesis⁴¹.

Animal Reservoir and transmission

Corona virus Infectious Disease-19 is a zoonotic illness, to control of "SARS-CoV"-2 dissemination must be abatement of the infections shedding to the environmental factors from the repositories and from people. that may advancement improvement of "SARS-CoV"-2 immunizations and therapeutics⁴² from data of phylogenetic examinations attempted with possible full genome groupings, bats appear to be the repository of SARS COV2⁴³. A coronavirus from a creature could most likely have been spread to a human, either straightforwardly or by a moderate host which tainted by infection and speak to a transmission creature model, for example, ferrets, civets or fish^{42,44}. Andersen and his colleagues unfaltering that the most possible birthplaces for "SARS-CoV"-2 checked one of two expected states dependent on genomic sequencing examination of infections:

1. The virus has adapted to its modern pathogenic status by natural choice in an animal host and then spread to humans. While there are no known instances of direct bat-human contact, it is assumed that an indirect host will be involved between bats and humans.
2. The virus's non-pathogenic form transferred from the animal to humans and then shifted to its new infectious status within the human populace⁴⁵. Generally recombination gives new variants when the cell host infected by different viruses of the similar species then the proofreading may maintenance the

choice of recombinant viruses strain in inhabitants⁴⁴. Actually, one of the major mechanisms complicated in the emergence of human SARS CoV strains from bat and civet ancestors was the recombination between the genes of the subunits of the spike⁴⁵. **Figure 1** offers a schematic of animal groups that may play a role in the development of human coronaviruses. the contribution of each Human coronavirus may differ extensively For eg, from year to year, 229E contributes as little as 1% to acute respiratory infections in the population in one year and up to 35% in the next. In fact, behavior can be hetrogenic in specific geographic areas of the same country⁴⁶.




Figure 1. The animal groups representing natural hosts for the coronaviruses⁴³

Transmission of "SARS-CoV"-2 happens for the most part (Human-to-human) between relatives⁴⁷. the researchers found that the "SARS-CoV"-2 genome structure varied incredibly from those of recently known coronaviruses⁴⁸. "Transmission between headed out to polluted territory happened in 31.3% while between social insurance representatives occurred in 3.8% of COVID-19 patients, gave by the National Health Commission of China on 14 February 2020". Then again, transmission of "SARS-CoV" and MERS-CoV is recognized as happening principally through nosocomial transmission, diseases of clinical professionals in 33–42% of SARS cases, and transmitting between patients (62–79%) was the most natural wellspring of contamination in MERS-CoV cases⁴⁹. Direct connection with middle host creatures or ingestion of wild creatures was believed to be the fundamental course of "SARS-CoV"-2 spread. By the by, the source(s) and transmission routine(s) of "SARS-CoV"-2 stay subtle⁵⁰.

Laboratory diagnosis

When samples are collected, the biological safety conditions must be taken into consideration, depending on in terms of maintaining personal safety reported in CDC, and they are collected by health care workers or laboratory professionals⁵¹ the isolation of samples from those infected with the virus is carried out at BSL-3 laboratories, while routine tests are performed in BSL-2 laboratories^{52,53}.

Specimens collection: On April eighth, CDC Organization clarified the example types and need. The gathering size of tests is 2-3 ml:- Upper respiratory: nasopharyngeal swab (NP), Oropharyngeal swab (OP), the engineered fiber swabs with plastic shafts are utilized, the swab put in 2-3 ml of viral transport medium.- Lower respiratory: bronchoalveolar lavage, tracheal suction in serious respiratory sickness, sputum (rinse the mouth with water then expectorate profound hack sputum legitimately into a sterile watertight screw top sputum assortment cup or clean dry holder. on the off chance that both NP and OP gathered ought to be joined at assortment into a solitary vial for amplifying test affectability and breaking point testing assets. The NP swab is increasingly delicate, however it can commit an error in finding and may should be taken from a more profound region by bronchoscopy⁵⁴. "SARS-CoV" and MERS-CoV RNA are distinguished from stool, pee and blood examples, yet the outcomes less dependably than from respiratory examples^{55,56}. Timing and most noteworthy viral titers of examples may improve affectability of quick tests recognizable proof for HCoV⁵⁷. All examples ought to contain data, for example, the date of patient contact or the introduction of the sickness, the patient's condition on the off chance that he has extreme or moderate side effects and the sort of test notwithstanding the date the example was collected⁵³.

Storage and Shipping: samples for viral detection must be reached laboratory as soon as possible and Store specimen at 4-8 C° for more than 72 days, and storage in -70 C° for below if delay of the testing or shipping. The specimens packaged, shipping and transporting are just like the UN Model Regulation, and any other applicable regulations depending on the mode of transport being used. A viral transport medium should be used when the samples are transported late and kept at a level of 20-70 taking into account the non-repeated melting and freezing of the sample^{58,59}.

Molecular Methods: The CDC 2019 –n COV Real time RT- PCR Diagnostic panel for detection and diagnosis of 2019-n COV based on amplification of viral nucleic acid. The upper and lower respiratory tract specimens collected from individuals who contact or confirmed cases with COVID-19 suitable for this technique. The results of his technique are included: Positive results are indicative active infection, while the negative results are not 2019 –n COV, the negative results could not be used as sole basis or treatment they must be combined with the history of patient if he had traveling history, clinical observation and epidemiological information. Many factors lead to the formation of negative results as: the poor quality of the sample being small in size, the delay in taking the sample or collecting it sooner than the appearance of the infection, not handling the sample correctly in terms of correct storage and charging it appropriately or due to technical reasons present in the sample itself such as viral mutations and PCR inhibition. Laboratories that test 19-covid samples, especially in countries where the virus was not previously known. The relevant WHO provides confirmatory testing For 5 positive samples and 10 negative samples collected from patients who are

appropriate to determine the case by referring it to a relevant WHO laboratory that provides confirmatory testing⁶⁰.

Serological Methods: It is difficult to diagnose the virus with serological tests and make it a routine work for diagnosis due to the difficulty in obtaining solutions and commercial materials for the purpose of diagnosis. Serological tests support molecular analyzes if the samples are negative, Serum can be tested in ELISA technique For IgG and IgM detecting^{61,62}. The utilization of colloidal gold-named immunoglobulin G (IgG) as the identification reagent is a system that can expand the affectability of quick antigen tests for respiratory viruses⁶³. The timing of the assortment of examples, where viral titers are most noteworthy, can help the analytic affectability of fast antigen tests for HCoV⁶⁴.

Finding by Radiation: X-beam check in the primary phase of the sickness presentations and CT filters show an crucial role in the diagnosis of ARS and pneumonia just as in the early discovery the danger of lung variations from the norm and secondary infection⁶⁵. Ground-glass mistiness was the major finding in subordinate lung projections; the development of lung illness confounded three styles of ground-glass, solidification and absurd clearing in the proceeding with stages at 5–8 days, while obscure solidification framed the overarching capacity in the incomparable stages at 9–13 days⁶⁶.

Treatment:

When CoV-2 SARS the injury was suspected in January 2020, the World Health Organization issued directives for the for clinically administering SARS⁶⁷. Approved antivirals that did not exist yet "SARS-CoV"-2 infection. As a result, the virus is disabled and preventive measures stopped to controller the extent of the illness, it is very necessary Approved antivirals that did not exist yet "SARS-CoV"-2 infection. This virus can be disabled by using ethanol 62-71%, 0.5% hydrogen Peroxide, formaldehyde 0.7-1%, glutaraldehyde 2%, 0.1% sodium hypochlorite, or 0.23% Povidone longings through a minute. Additional antiseptics as 0.55% orthophthalaldehyde, 0.02% chlorhexidine dicluconate, or benzalkonium chloride 0.05-0.2% is littler effective⁶⁸. Although each country and region with or without outbreaks of COVID-19 Follow strict prevention or prevention measures, and reported monitoring strategies. World Health Organization; Food and Drug Administration (FDA), COV-2 SARS have spread worldwide, So researchers from all over the world are working around the clock to find ways to slow the spread of the novel⁶⁹.

Clinical medication has endorsed numerous drugs for utilize hostile to "SARS-CoV"-2 infectivity for clinical preliminaries, as: lopinavir/ritonavir[70] It is a typical amalgamation of a profoundly pertinent twofold protease inhibitor (PI) against viral operators. a pivotal chemical for assembling of virion. [\[https://link.springer.com/article/10.2165/00003495-200363080-00004\]](https://link.springer.com/article/10.2165/00003495-200363080-00004), Arbidol⁷⁰ (that arbidol restrains numerous gatherings of infections by meddling with a few stages of an infection copy cycle⁷¹. Interferon-alpha⁷⁰ (it

is emitted by various kinds of cells, particularly the plasmacytoid dendritic cells, when the viral segments are perceived by the example acknowledgment receptor (PRR), so IFN-I is among the principal cytokines to deliver when viral infection⁷². The main kind of IFNs-a/b is expansive range antivirals, which show an immediate restraint of viral proliferation and along these lines improve the insusceptible reaction to a reasonable infection contamination^{73,74}. were the first to propose a remedial viability in COVID-19 ailment for IFN- α 2b, which is accessible antiviral mediation. Additionally, it surpasses the clinical advantage of the distinct patient, usage of IFN - α 2 b may likewise profit general wellbeing measures focused on hinder the tide of the scourge, in that time of viral shedding seems to abbreviate. Favipiravir⁷⁰ (Favipiravir is a pyrazine carboxamide subsidiary (T-705; 6-fluoro-3-hydroxy-2-pyrazinecarboxamide) and expansive range inhibitor of viral RNA polymerase, Favipiravir is a prodrug, that is "ribosylated and phosphorylated intracellularly" to shape the dynamic metabolite favipiravir ibofuranosyl-5'-triphosphate (T-705-RTP)⁷⁵. Chloroquine phosphates⁷⁰ this medicate "A clinically endorsed tranquilize" that is successful against jungle fever, and is known to cause antiviral impacts against numerous infections, including "SARS-CoV" and HCoV-229E⁷⁶. All in all, in vivo investigations it couldn't exhibit the counter popular adequacy of chloroquine against SARS - CoV⁷⁷. There was another investigation demonstrated Chloroquine anticoronaviral properties by testing antiviral exercises in vitro and in vivo against bunch 2 HCoV-OC 43 infection. In vitro antiviral analyses, chloroquine showed in vitro antiviral properties against the replication of HCoV-OC43 in HRT-18 cells, with an EC50 of 0.306 mM⁷⁸. Darunavir/Cobicistat⁷⁰ also A drug is an anti-retroviral combination tablet with a fixed dosage set to treat HIV-1 infection. The way this drug works is by selectively inhibiting the sites of cleavage of HIV-1 encoded Gag-Pol proteins in infected cells, and therefore the mature virus particles do not form [<https://www.clinicaltrialsarena.com/projects/prezcobix-darunavircobicistat-for-the-treatment-of-hiv-1/>]. Oseltamivir⁷⁰ this drug blocks the enzyme neuraminidase, the enzyme is expressed on the viral surface, and promotes the release of the virus from the affected cells and the movement of the virus is easy within the respiratory system. virions attach to the membrane of the affected cells and also entrapped with respiratory secretions in the presence of neuraminidase inhibitors⁷⁹, and methylprednisolone⁷⁰, this medication is a classic immunosuppressive drug, which is important to stop or delay the progression of pneumonia, and has been proven effective in treating acute respiratory distress syndrome (ARDS). A recent study discovered that managing methylprednisolone reduces the risk of death in COVID-19 pneumonia patients with ARDS, and therefore, who received methylprednisolone treatment, of whom 23 out of 50 patients died⁸⁰. Thus, other studies lead to that collective treatment of azithromycin and hydroxychloroquine has been investigated to decrease detection of viral RNA associated to the control group⁸¹.

However, concomitant cardiovascular diseases that are present in The study population, may partly explain the observation Cardiovascular toxicity and risk increased with use Chloroquine or hydroxychloroquine, especially when You use it with macrolides⁸². A study⁸³ stated that combining lopinavir and ritonavir "SARS-CoV" Clinically demonstrated benefits for patients (Less negative clinical outcomes) While⁸⁴ reported that lopinavir and ritonavir, two protease inhibitors failed totally to treatment this disease. Generally that Interferon beta-1b, Lopinavir and ritonavir are among "Middle East respiratory syndrome" patients infection in" the Kingdom of Saudi Arabia"⁸⁵. Preclinical evidence demonstrated of the effectiveness of remdesivir (broad spectrum antiviral nucleotide prodrug) to treat SARS- CoV and MERS- CoV infections⁸⁶. There are many preparations (formulations) containing minerals that have antiviral activity, including cheap, safe and readily available zinc⁸⁷. These formulations can be used as combination therapies or as adjuvant therapy aids with lopinavir-ritonavir, cyclosporine, monoclonal antibodies, remdesivir, ribavirin, interferon beta-1b, and antiviral peptides targeting 2019-nCoV⁸⁸. A monoclonal antibody, Tocilizumab that goals the interleukin 6 receptor. It has excellent safety features. So that monoclonal and Polyclonal antibodies are developed for 2019-nCoV for prevention after exposure⁸⁹. Pneumonia by COVID-19 seems to be a lung injury caused by the hyper activation immune effector cells. A great dose of vitamin C can lead to immunosuppression at the level of these effects. Hence, a high dose of vitamin C intravenously can be a useful and safe choice for management in the primary stages of COVID-19⁹⁰. Among recent immunotherapy treatments include the use of convalescent plasma or immunoglobulin as a choice for those who did not benefit from other treatments to improve the survival rate for SARS patients. Also, several studies have shown Shorter hospital stays and patient mortality were reduced when convalescence therapy than those who were Convalescent plasma is not treated⁹¹. As a treatment without severe damage complications, testing is important and effective in transferring plasma from those who recovered to patients SARS - CoV - 2⁹². Several monoclonal antibodies (mAbs) targeting non-RBD regions, particularly the N-terminal domain (NTD) has recently been reported⁹³. In addition to spike protein, two smaller proteins, E and M might also play important role in the viral assemblage of a coronavirus, and can boost the immune response against "SARS-CoV"⁹⁴. Recently there are studies that have shown the results of new X-ray crystallization results released from the major protein of "SARS-CoV"-2 (Mpro), computational methods within our plans⁹⁵. In order to contribute to the efficient treatment of "SARS-CoV"-e-2 and thus, increase velocity in mathematical analyzes are of these methods for the reason that they allow millions of data to be processed simultaneously⁹⁶. A set of computational methods and algorithms included in molecular anchoring that seeks through their targets to modern relationships between targets and chemical bonds through modeling direct physical interaction with them⁹⁷.

In a study⁹⁸, it was found that preparing to evaluate some drugs that are covalent and irreversible reactions, and which may have a strong epidemiological strategy. Simulation of molecular dynamics can provide many parts of the image obtained from covalent docking.

The biological treatments as melatonin (N-acetyl-5-methoxytryptamine) is a biologically active molecule and a recognized anti-inflammatory and antioxidant molecule, with a host of health-enhancing features; use melatonin Successfully treat delirium, sleep disorder, atherosclerosis and respiratory system viral diseases and infections. Melatonin is beneficial for critical care patients by reducing vascular permeability and anxiety, using anesthesia, and improving sleep quality, and it should be noted that melatonin is very safe which may also be beneficial for achieving better clinical outcomes for patients with COVID-19⁹⁹.

We desperately need extensive studies on this new virus in order to find ways to control its spread. In a study¹⁰⁰, this study required to obtain understandings for the design of a vaccine against "SARS-CoV"-2 through checking for elevation genetic similarities between "SARS-CoV"-2 and "SARS-CoV", which caused the disease to spread in 2003, and also benefit from present "SARS-CoV" immunological studies. By sifting experimentally identification B cells and T cells derived from "SARS-CoV" in "SARS-CoV" immune structural proteins, This study recognized a group of B-cell and T-cell-derived T cells from nucleocapsid (N) and the spike (S). Proteins that are completely identical to "SARS-CoV"-2.

The natural medicines as melatonin (N-acetyl-5-methoxytryptamine) is a biologically dynamic particle and a perceived mitigating and cancer prevention agent atom, with a large group of wellbeing upgrading highlights; use melatonin Successfully treat wooziness, rest issue, atherosclerosis and respiratory framework viral sicknesses and contaminations. Melatonin is advantageous for basic consideration patients by lessening vascular porousness and tension, utilizing sedation, and improving rest quality, and it ought to be noticed that melatonin is extremely sheltered which may likewise be useful for accomplishing better clinical results for patients with COVID-19⁹⁹.

We frantically need broad examinations on this new infection so as to discover approaches to control its spread. In an investigation¹⁰⁰, this examination required to get understandings for the structure of an antibody against "SARS-CoV"-2 through checking for rise hereditary similitudes between "SARS-CoV"-2 and "SARS-CoV", which made the infection spread in 2003, and furthermore advantage from present "SARS-CoV" immunological investigations. By filtering tentatively distinguishing proof B cells and T cells got from "SARS-CoV" in "SARS-CoV" safe auxiliary proteins, This investigation perceived a gathering of B-cell and T-cell-got T cells from nucleocapsid (N) and the spike (S). Proteins that are totally indistinguishable from "SARS-CoV"-2.

A study detailed that the viral S protein subunit immunizations delivered a high titer killing counter acting agent and full assurance from live-lessened "SARS-CoV", complete length S protein, and DNA-based S protein

antibodies. Protein antibodies that incorporate the protein S unit and immunizations that explicitly focus on the receptor restricting extent (RBD) of S1 subunit of viral S protein. Taken together, the objective site is the favored S protein/quality in the improvement of SARS antibody/Middle East Respiratory Syndrome¹⁰¹.

CONCLUSIONS

Researchers have gained ground in portraying the new coronavirus yet there are as yet numerous inquiries to be replied. contaminated individual is the central point in ailment transmission. Social insurance laborers should likewise follow CDC rules. Any transformation happening will be particularly significant. Further investigations are expected to describe how these distinctions influence the usefulness and pathogenesis of "SARS-CoV"-2.

REFERENCES

1. Cascella M., Rajnik M., Cuomo A., Dulebohn S.C. and Di Napoli R. "Features, Evaluation and Treatment Coronavirus (COVID-19)". In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2020.
2. Wang C., Horby P.W., Hayden F.G. and Gao G.F. "A novel coronavirus outbreak of global health concern". *Lancet*. 2020; 395(10223): 470-473. DOI: [10.1016/S0140-6736\(20\)30185-9](https://doi.org/10.1016/S0140-6736(20)30185-9).
3. Guan W.-J., Ni Z.-Y., Hu Y., Liang W.-H., Ou C.-Q., He J.-X., Liu L., Shan H., Lei C.-L. and Hui D.S. "Clinical characteristics of coronavirus disease 2019 in China". *New Engl. J. Med*. 2020; 382:1708-20.
4. Guo Y.-R., Cao Q.-D., Hong Z.-S., Tan Y.-Y., Chen S.-D., Jin H., Tan K.-S., Wang D.-Y. and Yan Y. "The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak—An update on the status". *Mil. Med Res*. 2020; 7: 1–10.
5. Lu R., Zhao X., Li J., Niu P., Yang B., Wu H., Wang W., Song H., Huang B. and Zhu N. "Genomic characterisation and epidemiology of 2019 novel coronavirus: Implications for virus origins and receptor binding". *Lancet*. 2020; 395: 565–574.
6. Woo P.C., Huang Y., Lau S.K. and Yuen K.Y. "Coronavirus genomics and bioinformatics analysis". *Viruses*. 2010; 2:1804–20.
7. Yin Y. and Wunderink R.G. "MERS, SARS and other coronaviruses as causes of pneumonia". *Respirology*. 2018; 23:130–7.
8. Tang X., Wu C., Li X., Song Y., Yao X., Wu X., Duan Y., Zhang H., Wang Y. and Qian Z. "On the origin and continuing evolution of SARS-CoV-2". *Natl. Sci. Rev*. 2020.
9. Islam M.T., Croll D., Gladioux P., Soanes D.M., Persoons A., Bhattacharjee P., Hossain M.S., Gupta D.R., Rahman M.M. and Mahboob M.G. (2016). "Emergence of wheat blast in Bangladesh was caused by a South American lineage of *Magnaporthe oryzae*". *BMC Biol*. 2016; 14: 84.
10. Phan T. "Genetic diversity and evolution of SARS-CoV-2". *Infect. Genet. Evol*. 2020; 81: 104260.
11. Shereen M.A., Khan S., Kazmi A., Bashir N. and Siddique R. "COVID-19 infection: origin, transmission, and characteristics of human coronaviruses". *J. Adv. Res*. 2020;

12. Zhang J., Zeng H., Gu J., Li H., Zheng L. and Zou Q. "Progress and Prospects on Vaccine Development against SARS-CoV-2". *Vaccines*(2020a). 8(2): 153.
13. Lam T.T-Y, Shum M.H-H, Zhu H-C., Tong Y-G, Ni X-B., Liao Y-S., Wei W., Cheung W.Y-M., Li W-J., Li L-F. "Identification of 2019-nCoV related coronaviruses in Malayan pangolins in southern China". 2020.
14. Tang X., Wu C., Li X., Song Y., Yao X., Wu X., Duan Y., Zhang H, Wang Y., Qian Z. "On the origin and continuing evolution of SARS-CoV-2". *National Science Review*. 2020.
15. Lu R., Zhao X., Li J., Niu P., Yang B., Wu H., Wang W., Song H., Huang B. and Zhu N. "Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding". *Lancet*. 2020; 395: 565-574.
16. Ralph R., Lew J., Zeng T., Francis M., Xue B., Roux M., Toloue Ostadgavahi A., Rubino S., Dawe N.J. and Al-Ahdal M.N. "2019-nCoV (Wuhan virus), a novel Coronavirus: human-to-human transmission, travel-related cases, and vaccine readiness". *J Infect Dev Ctries*. 2020; 14: 3-17.
17. Namy O., Moran S.J., Stuart D.I., Gilbert R.J., Brierley I. "A mechanical explanation of RNA pseudoknot function in programmed ribosomal frameshifting". *Nature*. 2006; 441: 244-247.
18. Fehr A.R. and Perlman S. "Coronaviruses: an overview of their replication and pathogenesis". *Methods Mol Biol*. 2015; 1282:1-23.
19. Muth D., Corman V.M., Roth H., Binger T., Dijkman R., Gottula L.T., Gloza-Rausch F., Balboni A., Battilani M. and Rihtaric D. "Attenuation of replication by a 29 nucleotide deletion in SARS-coronavirus acquired during the early stages of human-to-human transmission". *Sci Rep*. 2018; 8: 15177.
20. Islam M.T., Croll D., Gladieux P., Soanes D.M., Persoons A., Bhattacharjee P., Hossain M.S., Gupta D.R., Rahman M.M. and Mahboob M.G. "Emergence of wheat blast in Bangladesh was caused by a South American lineage of *Magnaporthe oryzae*". *BMC Biol*. 2016; 14: 84.
21. Yin C. "Genotyping coronavirus SARS-CoV-2: methods and implications". *Genomics*. 2020; Elsevier:12.
22. Rahman M.S., Hoque M.N., Islam M.R., Akter S., Rubayet-Ul-Alam A.S.M. and Siddique M.A. "Epitope-based chimeric peptide vaccine design against S, M and E 830 proteins of SARS-CoV-2 etiologic agent of global pandemic COVID-19: an in silico. 2020. Preprints, doi: <https://doi.org/10.1101/2020.03.30.015164>.
23. Shang W., Yang Y., Rao Y. and Rao X. "The outbreak of SARS-CoV-2 pneumonia calls for viral vaccines". *npj Vaccines*. 2020; 5(1): 1-3.
24. Tung P. "Genetic diversity and evolution of SARS-CoV-2". *Infection, genetics and evolution*. 2020; 81: 104260.
25. Chan J.F., Kok K.H., Zhu Z., Chu H., To K.K., Yuan S. and Yuen K.Y. "Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan". *Emerg Microbes Infect*. 2020; 9(1): 221-236.
26. Belouzard S., Millet J.K., Licitra B.N. and Whittaker G.R. "Mechanisms of coronavirus cell entry mediated by the viral spike protein". *Viruses*. 2012; 4: 1011-33.
27. Hilgenfeld R. "From SARS to MERS: Crystallographic studies on coronaviral proteases enable antiviral drug design". *FEBS J*. 2014; 281: 4085-96.
28. McBride R., van Zyl M. and Fielding B.C. "The coronavirus nucleocapsid is a multifunctional protein". *Viruses*. 2014; 6: 2991-3018.
29. Zhao Z., Li H. and Wu X. "Moderate mutation rate in the SARS coronavirus genome and its implications". *BMC Evol Biol*. 2004; 4: 21.
30. Domingo E., Sheldon J. and Perales C. "Viral quasispecies evolution". *Microbiol Mol Biol Rev*. 2012; 76: 159-216.
31. Ni M., Chen C. and Qian J. "Intra-host dynamics of Ebola virus during 2014". *Nat Microbiol*. 2016; 1: 16151.
32. Zhao W., Song S., Chen M., Zou D., Ma L., Ma Y., Li R., Hao L., Li C., Tian D., Tang B., Wang Y., Zhu J., Chen H., Zhang Z., Xue Y. and Bao Y. "The 2019 novel coronavirus resource". *Hereditas*. 2020; 42: 212-221.
33. Shen Z., Xiao Y., Kang L., Ma W., Shi L., Zhang L., Zhou Z., Yang J., Zhong J., Yang D., Guo L., Zhang G., Li H., Xu Y., Chen M., Gao Z., Wang J., Ren L. and Li M. "Genomic diversity of SARS-CoV-2 in coronavirus disease 2019 patients". *Clin. Infect. Dis*. 2020;
34. Zhou P., Yang X.L., Wang X.G., Hu B., Zhang L., Zhang W., Si H.R., Zhu Y., Li B. and Huang C.L. "A pneumonia outbreak associated with a new coronavirus of probable bat origin". *Nature*. 2020; 579: 270-273.
35. Coutard B., Valle C., de Lamballerie X., Canard B., Seidah N.G. and Decroly E. "The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade". *Antiviral Res*. 2020; 176: 104742.
36. Ge X.Y., Li J.L., Yang X.L., Chmura A.A., Zhu G., Epstein J.H., Mazet J.K., Hu B., Zhang W. and Peng C. "Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor". *Nature*. 2013; 503: 535-538.
37. Jeffers S.A., Tusell S.M., Gillim-Ross L., Hemmila E.M., Achenbach J.E., Babcock G.J., Thomas Jr., W.D., Thackray L.B., Young M.D. and Mason R.J. "CD209L (L-SIGN) is a receptor for severe acute respiratory syndrome coronavirus". *Proc. Natl. Acad. Sci. USA*. 2004; 101: 15748-15753.
38. Zhou P., Yang X.-L., Wang X.-G., Hu B., Zhang L., Zhang W., Si H.-R., Zhu Y., Li B. and Huang C.-L. "Discovery of a novel coronavirus associated with the recent pneumonia outbreak in humans and its potential bat origin". doi:<https://doi.org/10/1101/2020/01/22/914952>.
39. Chan J.F.W., Kok K.H., Zhu Z., Chu H., To K.K.W., Yuan S. and Yuen K.Y. "Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan." *Emerging microbes & infections*. 2020; 9(1): 221-236.
40. Koyama T., Platt D. and Parida L. "Variant analysis of COVID-19 genomes". *Bulletin of the World Health Organization*. 2020.
41. W.H.O. "Laboratory biosafety guidance related to the novel coronavirus (2019-nCoV)". 2020;
42. Kim Y.I., Kim S.G., Kim S.M., Kim E.H., Park S.J., Yu K.M., Chang J.H., Kim E.J., Lee S., Casel M.A.B. and Um J. "Infection and Rapid Transmission of SARS-CoV-2 in Ferrets". *Cell Host & Microbe*. 2020; 27(5): 704-709. E2. <https://doi.org/10.1016/j.chom.2020.03.023>.

43. Shereen A., Khan M., Kazmi S.A., Bashir N. and Siddique R. "COVID-19 infection: origin, transmission, and characteristics of human coronaviruses". *Journal of Advanced Research*. 2020; 24. DOI:[10.1016/j.jare.2020.03.005](https://doi.org/10.1016/j.jare.2020.03.005).
44. Kristian G., Andersen A.R., Lipkin W.L., Holmes E.C. and Garry R.F. "The proximal origin of SARS-CoV-2". *Nature Medicine*. 2020; 26: 450–455.
45. Minskaia E., Hertzog T., Gorbalenya A.E., Campanacci V., Cambillau C., Canard B., and Ziebuhr J. "Discovery of an RNA virus 335exoribonuclease that is critically involved in coronavirus RNA synthesis". *Proceedings of the National Academy of Sciences*. 2006; 103(13): 5108-13.
46. Eckert L.D., Becker M.M. and Halpin R.A. "Infidelity of SARS-CoV nsp14-exonuclease mutant virus replication is revealed by complete genome sequencing". *PLOS Pathog*. 2010; 6(5): e1000896.
47. Peiris J.S.M. "Coronaviruses". In *Medical Microbiology*. 2012; xx: 587–593.
48. Guan W.J., Ni Z.Y., Hu Y., Liang W.H., Ou C.Q., He J.X. "Clinical characteristics of coronavirus disease 2019 in China". *N Engl J Med*. 2020.
49. Kang C.K., Song K.H., Choe P.G., Park W.B., Bang J.H. and Kim E.S. "Clinical and epidemiologic characteristics of spreaders of middle east respiratory syndrome coronavirus during the 2015 outbreak in Korea". *J Korean Med Sci*. 2017; 32(5): 744–9.
50. Guo Y., Cao Q.-D., Hong Z.S., Tan Y., Chen S., Jin H.-J., Tan K.-S., Wang D.-Y. and Yan Y. "The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak – an update on the status". *Military Medical Research*. 2020; 7:11.
51. W.H.O. "Laboratory biosafety guidance related to the novel coronavirus (2019-nCoV)". 2020.
52. W.H.O. "Infection prevention and control during health care when novel coronavirus (nCoV) infection is suspected, interim guidance, January 2020. Geneva". 2020.
53. W.H.O. "Global Surveillance for human infection with coronavirus disease (COVID-2019), Interim guidance, Geneva". 2020.
54. Michael J. Loeffelholz M.J. and Tang Y.-W. "Laboratory diagnosis of emerging human coronavirus infections – the state of the art". *Emerging Microbes & Infections*. 2020; 9(1): 747-756.
55. Cheng P.K., Wong D.A., Tong L.K. "Viral shedding patterns of coronavirus in patients with probable severe acute respiratory syndrome". *Lancet*. 2004; 363 (9422): 1699–1700.
56. Poissy J., Goffar dA., Parmentier-Decrucq E. "Kinetics and pattern of viral excretion in biological specimens of two MERS-CoV cases". *J Clin Virol*. 2014; 61(2): 275–278.
57. Bruning A.H.L., Aatola H., Toivola H. "Rapid detection and monitoring of human coronavirus infections". *New Microbes New Infect*. 2018; 24: 52–55.
58. W.H.O. "Guidance to minimize risks for facilities collecting, handling or storing materials potentially infectious for polioviruses (PIM Guidance). Geneva". 2018.
59. W.H.O. "Guidance on regulations for the transport of infectious substances 2019–2020. Geneva". 2019.
60. Zhang W., Du R.-H., Li B., Zheng X.S., Yang X.-L., Hu B. "Molecular and serological investigation of 2019-nCoV infected patients: implication of multiple shedding routes". *Emerging Microbes & Infections*. 2020; 9(1): 386-389.
61. Li W., Liu L., Chen L. "Evaluation of a commercial colloidal gold assay for detection of influenza A and B virus in children's respiratory specimens". *Fetal Pediatr Pathol*. 2019; 15:1–6.
62. Chan C.M., Tse H., Wong S.S. "Examination of seroprevalence of coronavirus HKU1 infection with S protein-based ELISA and neutralization assay against viral spike pseudotyped virus". *J Clin Virol*. 2009; 45 (1): 54–60.
63. Shao X., Guo X., Esper F. "Seroepidemiology of group I human coronaviruses in children". *J Clin Virol*. 2007; 40(3): 207–213.
64. Bruning A.H.L., Aatola H., Toivola H. "Rapid detection and monitoring of human coronavirus infections". *New Microbes New Infect*. 2018; 24: 52–55.
65. Kim H. "Outbreak of novel coronavirus (COVID-19): What is the role of radiologists?". *Eur. Radiol*. 2020; in press.
66. Pan F., Ye T., Sun P., Gui S., Liang B., Li L., Zheng D., Wang J., Hesketh R.L. and Yang L. "Time course of lung changes on chest CT during recovery from 2019 novel coronavirus (COVID-19) pneumonia". *Radiology*. 2020; in press.
67. W.H.O. "Clinical Management of Severe Acute Respiratory Infection When Novel Coronavirus (nCoV) Infection Is Suspected". 2020. Available online: [https://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-\(ncov\)-infection-is-suspected](https://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected).
68. Kampf G., Todt D., Pfaender S. and Steinmann E. "Persistence of coronaviruses on inanimate surfaces and its inactivation with biocidal agents". *J. Hosp. Infect*. 2020; 104: 246–251.
69. Wei Q. and Ren Z. "Disinfection measures for pneumonia foci infected by novel 926 coronavirus in 2019". *Chin. J. Disinfect*. 2020; 37: 59-62.
70. Li H., Wang Y., Xu J. and Cao B. "Potential antiviral therapeutics for 2019 novel coronavirus". *Zhonghua Jie He He Hu Xi Za Zhi*. 2020; 43(0): E002. DOI: [10.3760/cma.j.issn.1001-0939.2020.0002](https://doi.org/10.3760/cma.j.issn.1001-0939.2020.0002).
71. Blaising J., Polyak S.J. and Pecheur E.I. "Arbidol as a broad-spectrum antiviral: an update". *Antivir. Res*. 2014; 107: 84–94.
72. Liu Y.-J. "IPC: professional type 1 interferon-producing cells and plasmacytoid dendritic cell precursors". *Annu. Rev. Immunol*. 2005; 23: 275–306.
73. Wang B.X. and Fish E.N. "Global virus outbreaks: interferons as 1st responders". *Semin Immunol*. 2019; 43:101300.
74. Zhou Q., Wei X.S., Xiang X., Wang X., Wang Z.H., Chen V. and Fish E.N. "Interferon- α 2b treatment for COVID-19". *MedRxiv*. 2020; DOI: [10.1101/2020.04.06.20042580](https://doi.org/10.1101/2020.04.06.20042580).
75. Furuta Y., Komeno T. and Nakamura T. "Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase". *Proc. Jpn. Acad. Ser. B Phys. Biol. Sci*. 2017; 93: 449–463.
76. Savarino A., Gennero L., Sperber K. and Boelaert J.R. "The anti-HIV-1 activity of chloroquine". *J. Clin. Virol*. 2001; 20: 131–135.
77. Barnard D.L., Day C.W., Bailey K., Heiner M., Montgomery R., Lauridsen L., Chan P.K., and Sidwel R.W. "Evaluation of immunomodulators, interferons and known in vitro SARS-CoV inhibitors for inhibition of SARS-CoV replication in BALB/c mice". *Antivir. Chem. Chemother*. 2006; 17: 275–284.
78. Keyaerts E., Li S., Vijgen L., Rysman E., Verbeeck J., Van Ranst M. and Maes P. "Antiviral activity of chloroquine against human coronavirus OC43 infection in newborn mice". *Antimicrobial agents and chemotherapy*. 2009; 53(8): 3416-3421.

79. Gubareva L.V., Kaiser L. and Hayden F.G. "Influenza virus neuraminidase inhibitors". *Lancet*. 2000; 355(9206): 827-835.
80. Wu C. "Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China". *JAMA Intern. Med.* 2020; e200994.
81. Gautret P. "Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial". *Int. J. Antimicrob.* 2020; 56(1): 105949. DOI: [10.1016/j.ijantimicag.2020.105949](https://doi.org/10.1016/j.ijantimicag.2020.105949).
82. Mehra M.R., Desai S.S., Kuy S., Henry T.D. and Patel A.N. "Cardiovascular disease, drug therapy, and mortality in COVID-19." *N Engl J Med.* 2020; 382:e102. DOI: [10.1056/NEJMoa2007621](https://doi.org/10.1056/NEJMoa2007621).
83. Chu C.M. "Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings". *Thorax*. 2004; 59: 252–56.
84. Cao B., Wang Y., Wen D., Liu W., Wang J., Fan G. "A trial of lopinavir–ritonavir in adults hospitalized with severe Covid-19". *N. Engl. J. Med.* 2020; 382(19):1787-1799. DOI: [10.1056/NEJMoa2001282](https://doi.org/10.1056/NEJMoa2001282).
85. Arabi Y.M., Alotman A., Balkhy H.H. "Treatment of Middle East respiratory syndrome with a combination of lopinavir-ritonavir and interferon-β1b (MIRACLE trial): study protocol for a randomized controlled trial". *Trials*. 2018; 19: 81.
86. Sheahan T.P., Sims A.C. and Leist S.R. "Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV". *Nat Commun.* 2020; 11: 222.
87. Barnard D.L., Wong M.H. and Bailey K. "Effect of oral gavage treatment with ZnAL42 and other metallo-ion formulations on influenza A H5N1 and H1N1 virus infections in mice". *Antivir Chem Chemother.* 2007; 18: 125–32.
88. Zumla A., Azhar E.I. and Arabi Y. "Host-directed therapies for improving poor treatment outcomes associated with the Middle East respiratory syndrome coronavirus infections". *Int J Infect Dis.* 2015; 40: 71–74.
89. Beigel J.H., Nam H.H., Adams P.L., Krafft A., Ince W.L. and El-Kamary S.S. "Advances in respiratory virus therapeutics - a meeting report from the 6th isriv Antiviral Group conference". *Antivir Res.* 2019; 167: 45-67.
90. Adnan E. "High-dose intravenous vitamin C treatment for COVID-19." 2020; DOI: [10.31219/osf.io/p7ex8](https://doi.org/10.31219/osf.io/p7ex8).
91. Clark D.R. and Jonathan E.M. "Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury". *Lancet.* 2020; 395(10223):473-475. DOI: [10.1016/S0140-6736\(20\)30317-2](https://doi.org/10.1016/S0140-6736(20)30317-2).
92. Chen L., Xiong J., Bao L. and Shi Y. "Convalescent plasma as a potential therapy for COVID-19". *The Lancet Infectious Diseases.* 2020; 20(4): 398-400.
93. Wang N. "Structural Definition of a Neutralization-sensitive Epitope on the MERS-CoV S1-NTD". *Cell Rep.* 2019; 28(13): 3395-405.
94. Schoeman D. and Fielding B.C. "Coronavirus envelope protein: current knowledge". *Virology*. 2019; 16: 69.
95. Cameron D., Bodenreider O., Yalamanchili H., Danh T., Vallabhaneni S., Thirunarayan K., Sheth A.P. and Rindflesch T.C. "A graph-based recovery and decomposition of Swanson's hypothesis using semantic predications". *Journal of biomedical informatics.* 2013; 46(2): 238–251.
96. Gupta M.K. "In-silico approaches to detect inhibitors of the human severe acute respiratory syndrome coronavirus envelope protein ion channel". *Journal of Biomolecular Structure and Dynamics.* 2020: 1–11. DOI: [10.1080/07391102.2020.1751300](https://doi.org/10.1080/07391102.2020.1751300).
97. Aanouz I. "Moroccan Medicinal plants as inhibitors of COVID-19: Computational investigations". *Journal of Biomolecular Structure and Dynamics.* 2020; 38: 1–12.
98. Al-Khafaji K., AL-Duhaidahawi L. D. and Taskin Tok T. (2020). "Using integrated computational approaches to identify safe and rapid treatment for SARS-CoV-2". *Journal of Biomolecular Structure and Dynamics.* 2020;1-11.
99. Reiter R.J., Ma Q. and Sharma R. "Treatment of Ebola and other infectious diseases: melatonin "goes viral". *Melatonin Res.* 2020: 43–57.
100. Ahmed S.F., Quadeer A.A. and McKay M.R. "Preliminary identification of potential vaccine targets for the COVID-19 coronavirus (SARS-CoV-2) based on SARS-CoV immunological studies". *Viruses.* 2020; 12(3): 254.
101. Buchholz U.J., Bukreyev A., Yang L., Lamirande E.W., Murphy B. R., Subbarao K. and Collins P.L. "Contributions of the structural proteins of severe acute respiratory syndrome coronavirus to protective immunity". *Proc. Natl. Acad. Sci. U. S. A.* 2004; 101 (26): 9804–9809.